Influence of long-term physical activity on serum PCSK9, HDL/LDL-cholesterol and lipoprotein a-levels

被引：0
|
作者：
Sponder, M. [1 ]
Campean, I. A. [1 ]
Dalos, D. [1 ]
Emich, M. [2 ]
Fritzer-Szekeres, M. [3 ]
Litschauer, B. [4 ]
Bergler-Klein, J. [1 ]
Graf, S. [1 ]
Strametz-Juranek, J. [1 ]
机构：
[1] Med Univ Vienna, Div Cardiol, Dept Internal Med 2, Vienna, Austria
[2] Med Univ Vienna, Fed Minist Def & Sports, Vienna, Austria
[3] Univ Vienna, Dept Med & Chem Lab Diagnost, Vienna, Austria
[4] Med Univ Vienna, Clin Pharmacol, Vienna, Austria
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1516
引用
收藏
页码：315 / 315
页数：1
相关论文
共 50 条
  • [21] Physical activity to reduce PCSK9 levels
    Tirandi, Amedeo
    Montecucco, Fabrizio
    Liberale, Luca
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [22] PCSK9 inhibitors tug of war: Compliance, adverse events and LDL-cholesterol target
    Sbrana, Francesco
    Dal Pino, Beatrice
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2025, 37 (02):
  • [23] PCSK9 Inhibition to Lower LDL-Cholesterol and Reduce Cardiovascular Risk Great Expectations
    Waters, David D.
    Hsue, Priscilla Y.
    CIRCULATION RESEARCH, 2015, 116 (10) : 1643 - 1645
  • [24] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
    Schwartz, Gregory G.
    Szarek, Michael
    Bittner, Vera A.
    Diaz, Rafael
    Goodman, Shaun G.
    Jukema, J. Wouter
    Landmesser, Ulf
    Lopez-Jaramillo, Patricio
    Manvelian, Garen
    Pordy, Robert
    Scemama, Michel
    Sinnaeve, Peter R.
    White, Harvey D.
    Steg, Ph Gabriel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (05) : 421 - 433
  • [25] Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol
    Seidah, Nabil G.
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2017, 24 (10) : 785 - 786
  • [26] Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol
    Nabil G Seidah
    Nature Structural & Molecular Biology, 2017, 24 : 785 - 786
  • [27] Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol
    Thomas F. Whayne
    Drugs, 2018, 78 : 287 - 291
  • [28] Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol
    Whayne, Thomas F.
    DRUGS, 2018, 78 (03) : 287 - 291
  • [29] EFFECTS OF LIPOPROTEIN APHERESIS (LA) ON SERUM PCSK9 LEVELS
    Julius, U.
    Rader, D.
    Gordon, B.
    Moriarty, P.
    Polk, D.
    Parhofer, K. G.
    ATHEROSCLEROSIS, 2014, 235 (02) : E59 - E60
  • [30] Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
    Hayat, Mahtaab
    Kerr, Robyn
    Bentley, Amy R.
    Rotimi, Charles N.
    Raal, Frederick J.
    Ramsay, Michele
    PLOS ONE, 2020, 15 (02):
12345